[1]刘斌,杨玉霞,刘杏,等.玻璃体内注射Lucentis治疗糖尿病黄斑水肿[J].眼科新进展,2015,35(1):045-47.[doi:10.13389/j.cnki.rao.2015.0013]
　LIU Bin,YANG Yu-Xia,LIU Xing,et al.Intravitreal injection of Lucentis for diabetic macular edema[J].Recent Advances in Ophthalmology,2015,35(1):045-47.[doi:10.13389/j.cnki.rao.2015.0013]
点击复制

玻璃体内注射Lucentis治疗糖尿病黄斑水肿
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
35卷
期数:
2015年1期
页码:
045-47
栏目:
应用研究
出版日期:
2015-01-05

文章信息/Info

Title:
Intravitreal injection of Lucentis for diabetic macular edema
作者:
刘斌; 杨玉霞; 刘杏; 李伟力; 莫正政
５１８０００　广东省深圳市，深圳爱视眼科专科门诊部
Author(s):
LIU Bin ;  YANG Yu-Xia ;  LIU Xing ;  LI Wei-Li ;  MO Zheng-Zheng
Eyeis Ophthalmology of Shenzhen , Shenzhen 518000, Guangdong Province, China
关键词:
Lucentis; 糖尿病黄斑水肿; 玻璃体内注射
Keywords:
Lucentis ;  diabetic macular edema; intravitreal injection
DOI:
10.13389/j.cnki.rao.2015.0013
文献标志码:
A
摘要:
目的　观察玻璃体内注射Ｌｕｃｅｎｔｉｓ治疗糖尿病黄斑水肿的效果。方法　确诊为糖尿病黄斑水肿者３０例３３眼，给予玻璃体内注射１０ｇ?Ｌ－１Ｌｕｃｅｎｔｉｓ０．０５ｍＬ，观察治疗前和治疗后１ｄ、１个月、３个月、６个月时患者的最佳矫正视力（ｂｅｓｔｃｏｒｒｅｃｔｅｄｖｉｓｕａｌａｃｕｉｔｙ，ＢＣＶＡ）、黄斑区中心凹厚度（ｃｅｎｔｒａｌｒｅｔｉｎａｌｔｈｉｃｋｎｅｓｓ，ＣＲＴ）和黄斑区１ｍｍ直径平均体积（ｃｅｎｔｒａｌｍａｃｕｌａｒｖｏｌｕｍｅ，ＣＭＶ），并分析患者治疗后３个月ＢＣＶＡ与性别、年龄、病程、治疗前ＢＣＶＡ、ＤＭＥ类型、ＣＲＴ和ＣＭＶ的变化之间的相关性。结果　３３眼治疗前后眼压差异均无统计学意义（Ｐ＞０．０５）。治疗前ＢＣＶＡ、ＣＲＴ、ＣＭＶ分别为（１５．６±１０．７）个字母数、（４９９．３±１８６．１）μｍ、（０．３３２±０．１３２）ｍｍ３。治疗后１ｄ、１个月、３个月、６个月的ＢＣＶＡ分别是（２１．７±１３．７）个字母数、（２５．２±１４．２）个字母数、（３０．７±１２．９）个字母数、（３０．２±１４．５）个字母数，ＣＲＴ分别为（４０７．４±１７６．５）μｍ、（３０３．８±９４．４）μｍ、（２３１．７±４３．３）μｍ、（２４４．９±６６．６）μｍ，ＣＭＶ分别为（０．２７８±０．１６１）ｍｍ３、（０．２２８±０．１０４）ｍｍ３、（０．２０５±０．０８９）ｍｍ３、（０．２０３±０．１１３）ｍｍ３。治疗后１ｄ、１个月、３个月、６个月的ＢＣＶＡ、ＣＲＴ、ＣＭＶ均优于治疗前（均为Ｐ＜０．０５）。治疗后各时间点间比较，除治疗后３个月与６个月间ＢＣＶＡ、ＣＲＴ、ＣＭＶ差异无统计学意义（均为Ｐ＞０．０５）外，其余各时间点间３项指标差异均有统计学意义（均为Ｐ＜０．０５）。治疗后３个月ＢＣＶＡ与病程、治疗前ＢＣＶＡ、ＣＲＴ和ＣＭＶ的变化相关（均为Ｐ＜０．０５），与性别、年龄、ＤＭＥ类型不相关（均为Ｐ＞０．０５）。结论　玻璃体内注射Ｌｕｃｅｎｔｉｓ可以有效治疗糖尿病黄斑水肿，提高视力，且预后与治疗前ＢＣＶＡ、病程、治疗后黄斑水肿减轻程度具有相关性。
Abstract:
Objective To observe the clinical therapeutic efficacy of intravitreal injection of Lucentis for diabetic macular edema ( DME) . Methods Thirty cases of 33 eyes diagnosed as DME were collected.the intravitreal injection of 0. 05 mL Lucentis ( 10 g . L-’) was performed, and the best-corrected visual acuity ( BCVA) , central retinal thickness ( CRT ) and central macular volume ( CMV ) with 1mm diameter were measured and recorded at I day , I month .3 months ,6 months after injection. Then the relationship between BCVA at 3 months after injection and sexual, age, duration , BCVA before injection , type of DME , CRT , CMV were analyzed. Results There was no statistical difference in intraocular pressure before and after injection of all 33 eyes (P > 0. 05 ) . The BCVA.CRT and CMV before injection were 15 . 6 + 10. 7 , ( 499. 3 + 186. I ) Vm and(0. 332 +0. 132) mm3. The BCVA at I day ,1 month,3 months and 6 months after injection were 21. 7 + 13. 7 .25. 2 + 14. 2 ,30. 7 + 12. 9 and 30. 2 + 14. 5 , respectively. The CRT at those time points were ( 407. 4 + 176. 5 ) ym , ( 303. 8 + 94. 4) Vm , ( 231. 7 + 43. 3 ) ym and( 244. 9 + 66. 6) ym, respectively. The CMV were ( 0. 278 + 0. 161 ) mm3 , (0. 228 + 0. 104 ) mmJ . ( 0. 205 + 0. 089) mm3 and ( 0. 203 + 0. 113 ) mm3 , respectively. Except for 3 months and 6 months after injection , the BCVA .CRT and CMV at other time after injection were better than before injection, and the differences were statistical significant( all P < 0. 05 ) . The BCVA at 3 months after injection were related to the disease duration. preoperative BCVA . CRT and CMV changes ( all P < 0. 05 ) . had no relationship with sexual, age and type of DME ( all P > 0. 05 ) . Conclusions The intravitreal injection of Lucentis is effective for treating the DME and improving the BCVA, and the postoperative BCVA recovery are dependent to the preoperative BCVA , disease duration and postoperative DME degree.

相似文献/References:

[1]赵倩 金学民.Avastin联合黄斑格栅样光凝治疗糖尿病黄斑水肿的临床研究[J].眼科新进展,2013,33(2):000.
[2]沈强 张学东.糖尿病黄斑水肿的发病机制及治疗进展[J].眼科新进展,2012,32(2):000.
[3]赵勇 张卯年 任兵.激素缓释系统治疗糖尿病黄斑水肿新进展[J].眼科新进展,2012,32(10):000.
[4]曹薇 崔红平 张美萍.23G微切口玻璃体切割手术治疗糖尿病视网膜病变[J].眼科新进展,2013,33(11):000.
[5]张祺 冯劼 李培凤 金翼.Lucentis联合氪黄激光治疗视网膜分支静脉阻塞黄斑水肿的疗效观察[J].眼科新进展,2013,33(12):000.
[6]王博,吴京,马明,等. 玻璃体内注射雷珠单抗与曲安奈德治疗糖尿病黄斑水肿的疗效对比分析[J].眼科新进展,2015,35(3):246.[doi:10.13389/j.cnki.rao.2015.0066]
　WANG Bo,WU Jing,MA Ming,et al. Clinictid effect comparison of intravitreal lucentis and triamcinolone acetonide for diabetic macular edema[J].Recent Advances in Ophthalmology,2015,35(1):246.[doi:10.13389/j.cnki.rao.2015.0066]
[7]傅维娜,陈梅珠,王云鹏. Lucentis联合视网膜光凝治疗视网膜分支静脉阻塞继发黄斑水肿[J].眼科新进展,2015,35(3):270.[doi:10.13389/j.cnki.rao.2015.0072]
　FU Wei-Na,CHEN Mei-Zhu,WANG Yun-Peng. Intravitreal injection with lucentis combined with local retinal photocoagulation for macular edema secondary to branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2015,35(1):270.[doi:10.13389/j.cnki.rao.2015.0072]
[8]徐浩,白宁艳,吕鹏,等. 雷珠单抗玻璃体内注射与黄斑部格栅样光凝联合治疗糖尿病性黄斑水肿的疗效观察[J].眼科新进展,2015,35(8):781.[doi:10.13389/j.cnki.rao.2015.0215]
　XU Hao,BAI Ning-Yan,LV Peng,et al. Intravitreous injection of ranibizumab combined with macular grid photocoagulation for diabetic macular edema[J].Recent Advances in Ophthalmology,2015,35(1):781.[doi:10.13389/j.cnki.rao.2015.0215]
[9]李戴弟,高云霞,潘玲珍,等.Lucentis和Avastin治疗激光诱导恒河猴脉络膜新生血管模型的作用[J].眼科新进展,2016,36(5):423.[doi:10.13389/j.cnki.rao.2016.0113]
　LI Dai-Di,GAO Yun-Xia,PAN Ling-Zhen,et al.Therapeutic effects of Avastin and Lucentis on laser-induced choroidal neovascularization in thesus monkeys[J].Recent Advances in Ophthalmology,2016,36(1):423.[doi:10.13389/j.cnki.rao.2016.0113]
[10]董秀清,冯松福,柯晓云.应用光学相干断层扫描量化评估糖尿病黄斑水肿的临床研究[J].眼科新进展,2017,37(2):133.[doi:10.13389/j.cnki.rao.2017.0035]
　DONG Xiu-Qing,FENG Song-Fu,KE Xiao-Yun.Evaluating diabetic macular edema quantificationally by optical coherence tomography[J].Recent Advances in Ophthalmology,2017,37(1):133.[doi:10.13389/j.cnki.rao.2017.0035]

备注/Memo

备注/Memo:
佛山市医学类科技攻关项目（编号：２０１３０８０９８）
更新日期/Last Update: 2015-01-04